Issues related to pharmacy and prescription drug pricing; Issues relating to implementation of the No Surprises Act (PL 116-260); Issues related to price transparency.
2026 · 2nd Quarter (Apr 1 - June 30)
CIGNA CORPORATION AND SUBSIDIARIES
Filed by TIBER CREEK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 19, 2026
- Income
- $90,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK GROUP
- Filing UUID
- 2ffd7816-a2f5-43cf-af05-5862f796ba2b
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Pharmacy issues related to H.R. 8800/S. 4784 - National Defense Authorization Act for Fiscal Year 2027.
Issues related to H.R. 5582/S. 2355 - Patients Deserve Price Tags Act.
Issues related to Medicare drug coverage, specialty pharmacy, and general prescription drug pricing policy.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.